Lido Advisors LLC reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 16.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,100 shares of the medical equipment provider’s stock after selling 8,102 shares during the period. Lido Advisors LLC owned about 0.06% of Lantheus worth $4,091,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Jupiter Topco LLC purchased a new stake in shares of Lantheus in the 2nd quarter valued at $575,628,000. Reinhart Partners LLC. boosted its holdings in Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after acquiring an additional 34,501 shares during the period. Carmignac Gestion boosted its holdings in Lantheus by 0.9% during the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after acquiring an additional 12,100 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after acquiring an additional 582,661 shares during the period. Finally, Epoch Investment Partners Inc. grew its position in Lantheus by 59.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after acquiring an additional 242,222 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Lantheus Price Performance
Lantheus stock opened at $101.59 on Monday. The firm has a market capitalization of $6.64 billion, a P/E ratio of 25.02 and a beta of 0.01. The company has a current ratio of 3.25, a quick ratio of 3.06 and a debt-to-equity ratio of 0.42. Lantheus Holdings, Inc. has a twelve month low of $51.47 and a twelve month high of $111.86. The stock’s fifty day simple moving average is $100.32 and its 200-day simple moving average is $92.91.
Lantheus (NASDAQ:LNTH – Get Free Report) last released its earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.45. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The firm had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. During the same period last year, the business posted $1.27 earnings per share. Lantheus’s revenue was up 1.5% compared to the same quarter last year. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current fiscal year.
Analyst Ratings Changes
LNTH has been the topic of a number of recent research reports. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, October 15th. Leerink Partners set a $102.50 price objective on shares of Lantheus in a report on Monday, August 3rd. Finally, Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $107.44.
Read Our Latest Analysis on LNTH
Lantheus Company Profile
Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.
Featured Articles
- Five stocks we like better than Lantheus
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
